Related Experiment Videos
Interstitial microwave thermal therapy for prostate cancer
Michael D Sherar1, John Trachtenberg, Sean R H Davidson
1Division of Medical Physics, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, Canada. sherar@uhnres.utoronto.ca
Journal of Endourology
|November 19, 2003
Summary
Interstitial microwave thermal therapy offers a minimally invasive approach to treat prostate cancer by heating tumors. This method shows promise for patients with recurrent disease and future applications as a first-line treatment.
Area of Science:
- Oncology
- Medical Physics
- Biomedical Engineering
Background:
- Thermal therapy utilizes heat (>50°C) to induce tumor cell death via thermal coagulation.
- Various energy sources (radiofrequency, microwave, laser, ultrasound) can be employed for thermal therapy.
- Minimally invasive delivery methods are being investigated for thermal ablation techniques.
Purpose of the Study:
- To review current knowledge on interstitial microwave thermal therapy for prostate cancer.
- To present findings from an ongoing clinical trial for recurrent or persistent prostate cancer post-radiation.
- To discuss future directions in optimizing thermal therapy for prostate cancer treatment.
Main Methods:
- Review of existing literature on interstitial microwave thermal therapy.
- Analysis of data from a clinical trial involving patients with recurrent or persistent prostate cancer.
- Discussion of advancements in pretreatment planning, real-time monitoring, and control systems.
Main Results:
- Interstitial microwave thermal therapy is being evaluated in patients with recurrent or persistent prostate cancer.
- The therapy involves heating tumors to temperatures exceeding 50°C.
- Ongoing trials are exploring its efficacy in specific patient populations.
Conclusions:
- Interstitial microwave thermal therapy is a promising minimally invasive treatment for prostate cancer.
- Future advancements in planning and monitoring can personalize treatments.
- This therapy holds potential as a first-line treatment option for prostate cancer.